Trial Profile

A Phase 1, Open-label, Multicenter Study of LTZ-301 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LTZ 301 (Primary)
Indications Autoimmune disorders; Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; First in man
Sponsors LTZ Therapeutics

Most Recent Events

14 Aug 2025 Planned number of patients changed to 42.
14 Aug 2025 Status changed from planning to not yet recruiting.
24 Feb 2025 According to LTZ Therapeutics media release, the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for LTZ-301 intended to treat relapsed or refractory non-Hodgkin lymphoma (r/r NHL). This phase I trial expected to start in Q2 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com